Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:03:46.377Z.
Calculation as of: 2026-10-06T16:03:46.377Z.
Quote observation: 2026-10-06T16:00:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d8f500f051b8c2f6d9df2326c38ce0bcf8edb39987555b97daf7c0f1a95d0fd4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
LENZ Therapeutics, Inc.
Market Cap
$118.83M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| LENZ Therapeutics, Inc. (LENZ) | $118.83M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $117.29M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.03M | N/A |
| Genelux Corporation (GNLX)vs › | $116.59M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.63M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.08M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.09M | N/A |
| Cibus, Inc. (CBUS)vs › | $122.89M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $123.03M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.08M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
